您所在的位置: 品牌专栏
奥拉帕利联合度伐利尤单抗治疗卵巢癌的临床效果
2024-03-22
标签:
其他
  
浏览量:6418
本期精选3篇妇产科相关领域文章,对摘要进行了翻译,与妇产科同仁共读: 1.Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study 奥拉帕利联合度伐利尤单抗作为PARP抑制剂初治铂敏感复发性卵巢癌患者的治疗:一项II期多队列研究 2.Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes. 动态血糖监测指标与糖尿病患者妊娠结局的关联 3.Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. 贝伐珠单抗联合化疗,同时加用阿替利珠单抗治疗转移性、持续性或复发性宫颈癌的3期临床试验

评论(0)
精彩评论